Fulgent Genetics

FLGT

Market cap $839M

Fulgent Genetics, Inc. ( FLGT ) UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM EST Company Participants Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lu Li - UBS Investment Bank, Research Division Presentation Lu Li UBS Investment Bank, Research Division Great. Well, our next session is the management team from Fulgent Genetics.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10th at 5:00 PM Eastern Time Piper Sandler 37th Annual Healthcare Conference on Tuesday, December.

Fulgent Genetics, Inc. ( FLGT ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Lu Li - UBS Investment Bank, Research Division David Westenberg - Piper Sandler & Co., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Greetings, and welcome to the Fulgent Genetics Q3 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to earnings of $0.31 per share a year ago.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Results: Revenue of $84.1 million, growing 17% year-over-year GAAP loss of $6.6 million, or ($0.21) per share Non-GAAP income of $4.5 million, or $0.14 per share Adjusted EBI.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2025 financial results before the market opens on Friday, November 7, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer que.

Explore the exciting world of Fulgent Genetics (FLGT 2.11%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics and anatomic pathology are positioned for sustainable double-digit revenue growth driven by innovation, increased insurance coverage, and geographic expansion. Meanwhile, Fulgent's Pharma segment continues to make steady progress, while cash burn remains moderate ($25 million in 2025).

Fulgent (FLGT) Q2 Revenue Jumps 16%